Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background Effectiveness data on novel oral anticoagulants (NOACs) versus warfarin for
stroke prevention in non-valvular atrial fibrillation (NVAF) by prior warfarin use are limited …

Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial
fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor …

BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with
atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

To assess the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with
atrial fibrillation (AF) after the use of rivaroxaban or warfarin. To investigate the effects of …

Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …